Published in J Immunol on June 01, 1974
Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease. J Clin Invest (1976) 5.96
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med (1998) 2.65
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 2.19
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med (1978) 2.10
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (1982) 1.93
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature (2008) 1.88
The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med (1999) 1.84
Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.76
Detection of immune complexes by a new assay, the polyethylene glycol precipitation-complement consumption test (PEG-CC). Clin Exp Immunol (1979) 1.74
Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci U S A (1981) 1.69
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Acute phase proteins and C9 in patients with Behcet's syndrome and aphthous ulcers. Clin Exp Immunol (1976) 1.66
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62
Interactions of C-reactive protein with the complement system. III. Complement-dependent passive hemolysis initiated by CRP. J Exp Med (1975) 1.48
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J Clin Invest (1982) 1.47
Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol (1979) 1.44
C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest (2000) 1.42
Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol (1982) 1.37
Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One (2010) 1.35
Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology (2003) 1.33
Oral ulceration and Behçet's syndrome. Gut (1977) 1.31
Expression of C-reactive protein in the human respiratory tract. Infect Immun (2001) 1.31
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
The structure of C-polysaccharide from the walls of Streptococcus pneumoniae. Biochem J (1978) 1.21
C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med (1985) 1.20
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J (2007) 1.19
Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci U S A (1982) 1.16
Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem (2009) 1.15
Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog (2009) 1.10
Human C-reactive protein does not bind to FcgammaRIIa on phagocytic cells. J Clin Invest (2001) 1.07
Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci U S A (2011) 1.04
Binding of human C-reactive protein to bacteria. Infect Immun (1982) 1.02
Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis (2007) 1.01
Studies on the interactions between C-reactive protein and complement proteins. Immunology (2007) 1.01
Hamster female protein. A new Pentraxin structurally and functionally similar to C-reactive protein and amyloid P component. J Exp Med (1981) 1.01
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol (2006) 1.01
Natural IgM mediates complement-dependent uptake of Francisella tularensis by human neutrophils via complement receptors 1 and 3 in nonimmune serum. J Immunol (2012) 1.00
Activation of platelets by modified C-reactive protein. Immunology (1982) 1.00
C-reactive protein protects against preerythrocytic stages of malaria. Infect Immun (1989) 0.99
Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun (2000) 0.97
Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol (1993) 0.96
Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (1982) 0.95
Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunology (1989) 0.95
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J Immunol (2007) 0.95
IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol (2005) 0.95
Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS One (2013) 0.94
Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J (2002) 0.94
Serum protein concentrations during Schistosoma mansoni infection in intact and T-cell deprived mice. I. The acute phase proteins, C3 and serum amyloid P-component (SAP). Immunology (1980) 0.93
Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med (1992) 0.93
Pentraxins and Fc receptors. Immunol Rev (2012) 0.92
Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation. J Infect Dis (2014) 0.91
Partial amino-acid sequences of human and rabbit C-reactive proteins: homology with immunoglobulins and histocompatibility antigens. Proc Natl Acad Sci U S A (1977) 0.90
'In vitro' study of a reaction between the complement system and cellular DNA. Immunology (1978) 0.90
Comparison of the enzymatic sensitivities of the platelet receptor for human C-reactive protein and its functional relationship to the platelet IgG Fc receptor. Clin Exp Immunol (1982) 0.89
The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets (2008) 0.89
Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the Health in Men Study. Int J Epidemiol (2009) 0.89
Isolation and characterization of guinea-pig serum amyloid P component. Immunology (1986) 0.88
Mannose-binding lectin does not act as an acute-phase reactant in adults with community-acquired pneumococcal pneumonia. Clin Exp Immunol (2006) 0.88
Perivascular deposits of serum proteins in cerebral cortex in vascular dementia. Acta Neuropathol (1985) 0.88
Differential correlation between interleukin patterns in disseminated and chronic human paracoccidioidomycosis. Clin Exp Immunol (1995) 0.87
C-Reactive protein gene variants are associated with postoperative C-reactive protein levels after coronary artery bypass surgery. BMC Med Genet (2009) 0.87
Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system. Immunology (1991) 0.87
Comparative studies of serum and synovial fluid C reactive protein concentrations. Ann Rheum Dis (1987) 0.86
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One (2013) 0.86
Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm (2014) 0.86
C-reactive protein in human atherogenesis: facts and fiction. Mediators Inflamm (2014) 0.86
Determination of dermatology life quality index, and serum C-reactive protein and plasma interleukin-6 levels in patients with chronic urticaria. Postepy Dermatol Alergol (2013) 0.86
Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors. Curr Opin Organ Transplant (2011) 0.86
PTX3 controls activation of matrix metalloproteinase 1 and apoptosis in conjunctivochalasis fibroblasts. Invest Ophthalmol Vis Sci (2012) 0.85
CRP and neutrophils: functional effects and complex uptake. Clin Exp Immunol (1986) 0.85
A computational and experimental study of the regulatory mechanisms of the complement system. PLoS Comput Biol (2011) 0.85
The role of complement in the induction and regulation of immune responses. Immunology (1984) 0.84
C1q binding activity in the sera of patients with chronic lung diseases. Clin Exp Immunol (1981) 0.84
Changes in plasma IL4, TNFá and CRP in response to regular passive smoking at home among healthy school children in Khartoum, Sudan. Afr Health Sci (2012) 0.83
Exacerbation of experimental poly-D-lysine arthritis by C-reactive protein. Agents Actions (1982) 0.83
Research pointers: Association of common genetic variant with susceptibility to invasive pneumococcal disease. BMJ (2002) 0.82
C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes. Arthritis Rheum (2013) 0.82
Evaluation of a C-reactive protein latex agglutination detection test with sera from patients with sexually transmitted diseases. J Clin Microbiol (1984) 0.81
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis (2005) 0.81
Occurrence of C-reactive protein in cryoglobulins. Clin Exp Immunol (2001) 0.81
Calcium-dependent binding of rabbit C-reactive protein to supported lipid monolayers containing exposed phosphorylcholine group. Biophys J (1999) 0.80
Interactions of C-reactive protein and complement with liposomes. Proc Natl Acad Sci U S A (1977) 0.80
Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vasc Health Risk Manag (2009) 0.80
The innate immune system and transplantation. Cold Spring Harb Perspect Med (2013) 0.79
Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J (2009) 0.79
The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein. Immunology (1998) 0.79
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA (1996) 9.45
Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet (1995) 4.31
Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J Clin Invest (1967) 4.31
Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science (1997) 3.92
Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med (1971) 3.32
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis (1974) 3.01
Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med (1977) 2.92
Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science (1991) 2.56
Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer (1974) 2.36
Malarial antibodies and autoantibodies to heart and other tissues in the immigrant and indigenous peoples of Uganda. Lancet (1968) 2.35
The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. Genes Dev (1995) 2.19
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17
Rabbit C1q: purification, functional and structural studies. J Immunol Methods (1972) 2.15
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Adipsin and complement factor D activity: an immune-related defect in obesity. Science (1989) 1.87
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 1.84
Autoimmunity to the heart in cardiac disease. Current concepts of the relation of autoimmunity to rheumatic fever, postcardiotomyand postinfarction syndromes and cardiomyopathies. Am J Cardiol (1969) 1.79
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis (1990) 1.75
Complement activation by C-reactive protein complexes. Ann N Y Acad Sci (1982) 1.75
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature (1979) 1.75
A QUANTITATIVE STUDY OF THE FIBRINOLYSIN-ANTIFIBRINOLYSIN REACTION. Science (1945) 1.74
Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans. J Am Acad Dermatol (1985) 1.71
Fatal adenovirus disease and human immunodeficiency virus infection. Pediatr Infect Dis J (1990) 1.69
Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol (1974) 1.68
Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by a commercial enzyme immunoassay. J Clin Microbiol (1986) 1.67
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet (1988) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A (2001) 1.59
Antibodies to mycobacteria in human tuberculosis. I. Development of antibodies before and after antimicrobial therapy. J Infect Dis (1980) 1.56
Demonstration of an antibody to proximal tubular antigen in the pathogenesis of experimental autoimmune nephrosis in rats. J Lab Clin Med (1969) 1.55
In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol (1987) 1.51
Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev Infect Dis (1984) 1.51
Cryptococcosis in a cancer hospital: clinical and pathological correlates in forty-six patients. Cancer (1977) 1.49
Characterization of murine BATF: a negative regulator of activator protein-1 activity in the thymus. Eur J Immunol (2001) 1.45
Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol (1997) 1.43
Immune complexes in congenital and natal cytomegalovirus infections of man. J Clin Invest (1977) 1.42
Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol (1987) 1.42
Clinical manifestations and therapy of Lactobacillus endocarditis: report of a case and review of the literature. Rev Infect Dis (1986) 1.41
Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol (2010) 1.40
Cross-reaction of group A streptococci and heart tissue: varying serologic specificity of cross-reactive antisera and relation to carrier-hapten specificity. Transplant Proc (1969) 1.39
IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol (2001) 1.39
Steroids for Pneumocystis carinii pneumonia and respiratory failure in the acquired immunodeficiency syndrome. A reassessment. Arch Intern Med (1990) 1.38
Chlamydia trachomatis in suburban adolescents. J Pediatr (1987) 1.36
Viridans streptococcal endocarditis: clinical, microbiological, and echocardiographic correlations. J Infect Dis (1986) 1.35
Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc Natl Acad Sci U S A (1991) 1.34
Stat4 regulates multiple components of IFN-gamma-inducing signaling pathways. J Immunol (2000) 1.33
Human factor D of the alternative complement pathway: purification and characterization. J Immunol (1977) 1.33
Autoantibodies to heart and rheumatic fever: the induction of autoimmunity to heart by streptococcal antigen cross-reactive with heart. Ann N Y Acad Sci (1965) 1.29
Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. Proc Natl Acad Sci U S A (1989) 1.29
Cutting edge: differential requirements for Stat4 in expression of glycosyltransferases responsible for selectin ligand formation in Th1 cells. J Immunol (2001) 1.28
Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen. J Clin Microbiol (1985) 1.28
Cutaneous nocardiosis. Case reports and review. J Am Acad Dermatol (1985) 1.28
Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med (1998) 1.22
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol (1981) 1.22
Immunopathologic studies of systemic lupus erythematosus (SLE). I. Tissue-bound immunoglobulins in relation to serum antinuclear immunoglobulins in systemic lupus and in chronic liver disease with LE cell factor. J Clin Invest (1967) 1.22
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Immune complexes and other laboratory features of pleural effusions: a comparison of rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Ann Intern Med (1980) 1.19
Modelling of the serine-proteinase fold by X-ray and neutron scattering and sedimentation analyses: occurrence of the fold in factor D of the complement system. Biochem J (1993) 1.19
C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res (1997) 1.18
Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol (1987) 1.17
Structure of human factor D. A complement system protein at 2.0 A resolution. J Mol Biol (1994) 1.17
Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice. J Biol Chem (1998) 1.17
Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity. J Mol Biol (1998) 1.16
The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol (1992) 1.16
Cutaneous infection at dog bite wounds associated with fulminant DF-2 septicemia. Am J Med (1985) 1.16
Cutting edge: differential expression of chemokines in Th1 and Th2 cells is dependent on Stat6 but not Stat4. J Immunol (2000) 1.15
The Arthus reaction in rodents: species-specific requirement of complement. J Immunol (2000) 1.14
The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression. J Immunol (2000) 1.13
Autoimmunity to heart and its relation to heart disease. Prog Allergy (1969) 1.13
Immune complex detection and complement activity in rheumatoid arthritis: a comparative study of a radioimmunoassay using monoclonal rheumatoid factor, gel diffusion techniques and C4 activity. Clin Exp Immunol (1978) 1.12
Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79. Public Health Rep (1984) 1.12
Comparison of two rapid culture methods for detection of cytomegalovirus in clinical specimens. J Clin Microbiol (1987) 1.10
Fall in human herpesvirus 6 seropositivity with age. Lancet (1988) 1.09
Translational regulation of complement protein C2 expression by differential utilization of the 5'-untranslated region of mRNA. J Biol Chem (1990) 1.09
Cytokine-stimulated T lymphocyte proliferation is regulated by p27Kip1. J Immunol (2000) 1.09
Stimulation of human neutrophil Fc receptor-mediated phagocytosis by a low molecular weight cytokine. J Immunol (1986) 1.09
C-reactive protein binding specificities: artificial and natural phospholipid bilayers. Ann N Y Acad Sci (1982) 1.08
Topology and structure of the C1q-binding site on C-reactive protein. J Immunol (2001) 1.08
"Nonspecific" stimulation of lymphocyte transformation by cellular fractions and acid extracts of group A streptococci. J Immunol (1971) 1.08
Rapid detection of influenza virus in cell culture by indirect immunoperoxidase staining with type-specific monoclonal antibodies. Diagn Microbiol Infect Dis (1987) 1.07
Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA (1988) 1.07
Structural basis of profactor D activation: from a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D. EMBO J (1999) 1.07
Cutaneous lesions in disseminated mucormycosis. JAMA (1973) 1.07
Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol (1992) 1.07
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07
Surface loops adjacent to the cation-binding site of the complement factor B von Willebrand factor type A module determine C3b binding specificity. Biochemistry (1997) 1.06
Opsonic properties of C-reactive protein. Stimulation by phorbol myristate acetate enables human neutrophils to phagocytize C-reactive protein-coated cells. J Immunol (1985) 1.06
In vitro biosynthesis of complement protein D by U937 cells. J Immunol (1985) 1.05
Age-related changes in serum immunoglobulins in patients with familial IgA deficiency and common variable immunodeficiency (CVID). Clin Exp Immunol (1997) 1.04
Molecular genetics, structure, and function of C-reactive protein. Immunol Res (1991) 1.04
Human complement proteins D, C2, and B. Active site mapping with peptide thioester substrates. J Biol Chem (1987) 1.04